12 Best Healthcare Stocks to Buy for 2026

Page 2 of 11

10. Argenx SE – ADR (NASDAQ:ARGX)

1-Year Gain: 27.35%

Upside Potential: 25.92%

Number of Hedge Fund Holders: 50

Argenx SE – ADR (NASDAQ:ARGX) is one of the best healthcare stocks to buy for 2026. On January 13, Argenx SE – ADR (NASDAQ: ARGX) saw its market sentiment boosted after the US Food and Drug Administration accepted priority review for a supplemental biologics license application for the immune disorder drug Vyvgart.

The company submitted the application to expand the use of candidate drugs for treating adults with acetylcholine receptor antibody-seronegative generalized myasthenia gravis (gMG). If successful, the license would broaden the patient population eligible for the medication. The FDA has already granted priority review status, which is expected to accelerate regulatory decision timelines for the expanded drug indication.

Earlier, on January 12, William Blair reiterated an Outperform rating on the stock, impressed by the company’s strong sales momentum in its Vyvgart franchise. Sales for the candidate drug continue to exceed expectations, with the momentum expected to continue throughout 2026 and across indications in MG (myasthenia gravis) and CIDP (chronic inflammatory demyelinating polyneuropathy)

The research firm is also confident in the company’s other clinical assets, including empasiprubart for MMN (multifocal motor neuropathy), which presents a blockbuster opportunity.

Argenx SE – ADR (NASDAQ:ARGX) is a Netherlands-based global biotechnology company focused on developing, manufacturing, and commercializing antibody-based therapies for severe autoimmune diseases and cancers.

Page 2 of 11